Skip to main content
. 2020 Sep 22;16(3):460–469. doi: 10.4103/1673-5374.293256

Figure 7.

Figure 7

Epac2 agonist S-220 attenuates LPS induced astrocyte activation in vitro.

Representative fluorescent images of control (A), LPS-treated (4 hours) (B) and LPS + S-220-treated (4 hours) (C) astrocytes. Scale bars: A–C 100 µm. (D) Quantification of the mean fluorescence intensity of GFAP showed significant difference between control and LPS-treated astrocytes, and between LPS and LPS + S-220-treated astrocytes. n = 3/group. ***P < 0.001. GFAP: Glial fibrillang acidic protein; LPS: lipopolysaccharide. Adapted from Guijarro-Belmar et al. (2019).